GRAIL, Inc. Faces Class Action Lawsuit for Securities Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against GRAIL, Inc. for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 13, 2025, and February 19, 2026, with a deadline to contact the firm by August 4, 2026.
- False Statement Allegations: The complaint alleges that GRAIL misled investors regarding the prospects of its NHS-Galleri trial for Stage III-IV cancers, concealing adverse facts while presenting the trial positively, resulting in investor losses when the truth emerged.
- Market Reaction Impact: GRAIL's overstated optimism about the NHS-Galleri study, which ignored data suggesting that the three-year timeframe was insufficient to demonstrate the successful achievement of the study's primary endpoint, rendered its public statements false and materially misleading throughout the class period.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to join the lawsuit to recover losses, highlighting its specialization in securities class action lawsuits and shareholder rights litigation to protect investor interests.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRAL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRAL
Wall Street analysts forecast GRAL stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 59.810
Low
38.00
Averages
60.86
High
83.71
Current: 59.810
Low
38.00
Averages
60.86
High
83.71
About GRAL
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GRAIL, Inc. Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against GRAIL, Inc. for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 13, 2025, and February 19, 2026, with a deadline to contact the firm by August 4, 2026.
- False Statement Allegations: The complaint alleges that GRAIL misled investors regarding the prospects of its NHS-Galleri trial for Stage III-IV cancers, concealing adverse facts while presenting the trial positively, resulting in investor losses when the truth emerged.
- Market Reaction Impact: GRAIL's overstated optimism about the NHS-Galleri study, which ignored data suggesting that the three-year timeframe was insufficient to demonstrate the successful achievement of the study's primary endpoint, rendered its public statements false and materially misleading throughout the class period.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to join the lawsuit to recover losses, highlighting its specialization in securities class action lawsuits and shareholder rights litigation to protect investor interests.
See More
Reminder of Shareholder Class Action Lawsuits
- Grail Lawsuit Details: The class action lawsuit against Grail, Inc. alleges that the company made materially false or misleading statements between May 13, 2025, and February 19, 2026, impacting investor decisions, with a deadline of August 4, 2026, for investors to apply as lead plaintiffs to protect their rights.
- Verra Lawsuit Overview: The class action lawsuit against Verra Mobility Corporation claims that the company failed to disclose its revenue outlook for the Commercial Services segment between February 24, 2026, and May 26, 2026, with investors needing to apply by August 4, 2026, to seek legal recourse as lead plaintiffs.
- BitGo Lawsuit Insights: The class action lawsuit against BitGo Holdings, Inc. alleges that the company did not adequately disclose the risks posed by falling digital asset prices to its financial performance, with a deadline of August 7, 2026, for investors to apply as lead plaintiffs to safeguard their interests.
- Law Firm Credentials: Holzer & Holzer, LLC is a top-rated securities litigation law firm that has recovered hundreds of millions for defrauded shareholders since its inception in 2000, emphasizing its commitment to providing robust legal representation for investors.
See More
GRAIL Faces Class Action Lawsuit for Securities Fraud
- Stock Price Plunge: GRAIL's stock dropped 50.55% from $101.53 to $50.21 following the February 19, 2026 announcement that its NHS-Galleri trial failed to meet its primary endpoint, severely impacting investor confidence and market performance.
- Class Action Initiated: A class action lawsuit has been filed by Bleichmar Fonti & Auld LLP on behalf of GRAIL investors, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, with investors required to apply to lead the case by August 4, 2026.
- Trial Design Controversy: GRAIL claimed its NHS-Galleri trial was designed for three years to reduce late-stage cancer cases, but the lawsuit argues this timeframe was insufficient to demonstrate the primary endpoint, potentially misleading investors about the company's prospects.
- Legal Consequences and Impact: The lawsuit could result in significant financial liabilities for GRAIL, affecting its future fundraising capabilities and market reputation, thereby intensifying investor skepticism regarding its business model.
See More
Class Action Lawsuit Announced for GRAIL, Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of GRAIL, Inc. (NASDAQ:GRAL) stock purchasers from May 13, 2025, to February 19, 2026, with a deadline of August 4, 2026, for investors to apply as lead plaintiffs, indicating that legal proceedings are underway.
- Potential Compensation Opportunity: Investors who purchased GRAIL common stock during the class period may be entitled to compensation without any out-of-pocket fees, which is likely to attract more affected investors to participate in the lawsuit, thereby increasing its overall impact.
- Lawsuit Background: The lawsuit alleges that defendants provided overly optimistic statements regarding the NHS-Galleri trial while concealing significant adverse facts related to the trial results, leading to investor losses once the true information was disclosed, highlighting the company's lack of transparency and information disclosure.
- Law Firm Reputation: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases, which may bolster investor confidence in this lawsuit.
See More
Class Action Lawsuit Filed Against GRAIL, Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against GRAIL, Inc., aiming to recover damages for investors who purchased GRAIL securities between May 13, 2025, and February 19, 2026, highlighting investor concerns over potential losses.
- False Statement Allegations: The complaint alleges that GRAIL executives made materially false statements regarding the likelihood of achieving significant cancer reduction in the NHS-Galleri trial, concealing adverse facts that misled investors about the company's prospects, which could negatively impact stock prices.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by August 4, 2026, to share in any potential recovery from the lawsuit, reflecting the legal system's role in protecting investor rights and interests.
- Law Firm's Strength: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that has recovered hundreds of millions for investors, emphasizing its expertise and successful track record in securities fraud class actions, which may enhance investor confidence in the lawsuit's potential outcomes.
See More
Grail Class Action Lawsuit Initiated Over Stock Misrepresentation
- Lawsuit Background: Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Grail, Inc., representing stock purchasers from May 13, 2025, to February 19, 2026, alleging violations of the Securities Exchange Act of 1934, which may lead to significant investor losses.
- Trial Result Misrepresentation: Grail failed to achieve the statistically significant reduction in Stage III-IV cancers in its NHS-Galleri trial, resulting in a stock price drop of over 50% on February 19, 2026, highlighting a severe discrepancy between management's optimistic projections and actual outcomes.
- Investor Rights: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Grail stock during the class period can seek to be appointed as lead plaintiff, representing other shareholders in the lawsuit to ensure their rights to potential recoveries.
- Law Firm Strength: Robbins Geller recovered over $916 million for investors in 2025, ranking first for the fourth time in five years, demonstrating its robust capabilities in securities fraud and shareholder rights litigation, thereby enhancing investor confidence in its representation.
See More
GRAIL, Inc. Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against GRAIL, Inc. for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 13, 2025, and February 19, 2026, with a deadline to contact the firm by August 4, 2026.
- False Statement Allegations: The complaint alleges that GRAIL misled investors regarding the prospects of its NHS-Galleri trial for Stage III-IV cancers, concealing adverse facts while presenting the trial positively, resulting in investor losses when the truth emerged.
- Market Reaction Impact: GRAIL's overstated optimism about the NHS-Galleri study, which ignored data suggesting that the three-year timeframe was insufficient to demonstrate the successful achievement of the study's primary endpoint, rendered its public statements false and materially misleading throughout the class period.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to join the lawsuit to recover losses, highlighting its specialization in securities class action lawsuits and shareholder rights litigation to protect investor interests.
See More
Reminder of Shareholder Class Action Lawsuits
- Grail Lawsuit Details: The class action lawsuit against Grail, Inc. alleges that the company made materially false or misleading statements between May 13, 2025, and February 19, 2026, impacting investor decisions, with a deadline of August 4, 2026, for investors to apply as lead plaintiffs to protect their rights.
- Verra Lawsuit Overview: The class action lawsuit against Verra Mobility Corporation claims that the company failed to disclose its revenue outlook for the Commercial Services segment between February 24, 2026, and May 26, 2026, with investors needing to apply by August 4, 2026, to seek legal recourse as lead plaintiffs.
- BitGo Lawsuit Insights: The class action lawsuit against BitGo Holdings, Inc. alleges that the company did not adequately disclose the risks posed by falling digital asset prices to its financial performance, with a deadline of August 7, 2026, for investors to apply as lead plaintiffs to safeguard their interests.
- Law Firm Credentials: Holzer & Holzer, LLC is a top-rated securities litigation law firm that has recovered hundreds of millions for defrauded shareholders since its inception in 2000, emphasizing its commitment to providing robust legal representation for investors.
See More
GRAIL Faces Class Action Lawsuit for Securities Fraud
- Stock Price Plunge: GRAIL's stock dropped 50.55% from $101.53 to $50.21 following the February 19, 2026 announcement that its NHS-Galleri trial failed to meet its primary endpoint, severely impacting investor confidence and market performance.
- Class Action Initiated: A class action lawsuit has been filed by Bleichmar Fonti & Auld LLP on behalf of GRAIL investors, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, with investors required to apply to lead the case by August 4, 2026.
- Trial Design Controversy: GRAIL claimed its NHS-Galleri trial was designed for three years to reduce late-stage cancer cases, but the lawsuit argues this timeframe was insufficient to demonstrate the primary endpoint, potentially misleading investors about the company's prospects.
- Legal Consequences and Impact: The lawsuit could result in significant financial liabilities for GRAIL, affecting its future fundraising capabilities and market reputation, thereby intensifying investor skepticism regarding its business model.
See More
Class Action Lawsuit Announced for GRAIL, Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of GRAIL, Inc. (NASDAQ:GRAL) stock purchasers from May 13, 2025, to February 19, 2026, with a deadline of August 4, 2026, for investors to apply as lead plaintiffs, indicating that legal proceedings are underway.
- Potential Compensation Opportunity: Investors who purchased GRAIL common stock during the class period may be entitled to compensation without any out-of-pocket fees, which is likely to attract more affected investors to participate in the lawsuit, thereby increasing its overall impact.
- Lawsuit Background: The lawsuit alleges that defendants provided overly optimistic statements regarding the NHS-Galleri trial while concealing significant adverse facts related to the trial results, leading to investor losses once the true information was disclosed, highlighting the company's lack of transparency and information disclosure.
- Law Firm Reputation: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases, which may bolster investor confidence in this lawsuit.
See More
Class Action Lawsuit Filed Against GRAIL, Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against GRAIL, Inc., aiming to recover damages for investors who purchased GRAIL securities between May 13, 2025, and February 19, 2026, highlighting investor concerns over potential losses.
- False Statement Allegations: The complaint alleges that GRAIL executives made materially false statements regarding the likelihood of achieving significant cancer reduction in the NHS-Galleri trial, concealing adverse facts that misled investors about the company's prospects, which could negatively impact stock prices.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by August 4, 2026, to share in any potential recovery from the lawsuit, reflecting the legal system's role in protecting investor rights and interests.
- Law Firm's Strength: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that has recovered hundreds of millions for investors, emphasizing its expertise and successful track record in securities fraud class actions, which may enhance investor confidence in the lawsuit's potential outcomes.
See More
Grail Class Action Lawsuit Initiated Over Stock Misrepresentation
- Lawsuit Background: Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Grail, Inc., representing stock purchasers from May 13, 2025, to February 19, 2026, alleging violations of the Securities Exchange Act of 1934, which may lead to significant investor losses.
- Trial Result Misrepresentation: Grail failed to achieve the statistically significant reduction in Stage III-IV cancers in its NHS-Galleri trial, resulting in a stock price drop of over 50% on February 19, 2026, highlighting a severe discrepancy between management's optimistic projections and actual outcomes.
- Investor Rights: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Grail stock during the class period can seek to be appointed as lead plaintiff, representing other shareholders in the lawsuit to ensure their rights to potential recoveries.
- Law Firm Strength: Robbins Geller recovered over $916 million for investors in 2025, ranking first for the fourth time in five years, demonstrating its robust capabilities in securities fraud and shareholder rights litigation, thereby enhancing investor confidence in its representation.
See More
